Market Overview

Biogen, Isis Pharma Announce Collaboration for Antisense Programs

Related BIIB
Is Illumina Worth Adding To Your Portfolio?
The Biotech Stock With The Most Upside In 2015, According To Morgan Stanley
Don't Panic Over Recent Tech Turmoil (Fox Business)
Related ISIS
CNBC's Stock Pops & Drops From December 16
3 Biotech ETFs Rally On Merger News
Making Money With Charles Payne: 10/08/14 (Fox Business)

 Biogen Idec (NASDAQ: BIIB) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that they have entered into a global collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders.  Biogen Idec and Isis are also developing antisense drugs to treat spinal muscular atrophy and myotonic dystrophy type 1 under previously established collaborations. 

Under the terms of the agreement, Isis will receive an upfront payment of $30 million and is responsible for the discovery of a lead antisense drug for each of the three undisclosed targets. Isis is eligible to receive substantial development milestone payments to support research and development of each program prior to the exercise by Biogen Idec of its option to license each program.  Biogen Idec has the option to license a drug from each of the three programs through the completion of Phase 2 trials. Isis could receive up to another $200 million in a license fee and regulatory milestone payments per program. In addition, Isis will receive double-digit royalties on sales of drugs. Isis will be responsible for development of the drugs through the completion of the initial Phase 2 clinical trial, with Biogen Idec providing advice and assistance on research and the clinical trial design and conduct and regulatory strategy for each program. If Biogen Idec exercises its option, it will assume global development, regulatory and commercialization responsibilities. 

Posted-In: News FDA


Related Articles (BIIB + ISIS)

Around the Web, We're Loving...

Get Benzinga's Newsletters